Phaseline

Companies › Hemab ApS

Hemab ApS: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 2; Hematology, Other; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sutacimig
Bispecific antibody binding activated factor VII and TLT-1 on platelets
F7, TREML1Phase 2Congenital Factor VII DeficiencyNov 2027
HMB-003–Phase 1Healthy Adult ParticipantsApr 2027
HMB-002
Von Willebrand factor (VWF) replacement or augmentation therapy
–Phase 1Von Willebrand Disease (VWD)Jul 2027
HMB-001
Bispecific antibody bridging platelet glycoprotein receptors to promote platelet aggregati
–Phase 1Glanzmann ThrombastheniaAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07798505HMB-003Phase 1Healthy Adult ParticipantsOtherApr 2027
NCT06754852HMB-002Phase 1Von Willebrand Disease (VWD)HematologyJul 2027
NCT06211634HMB-001Phase 1Glanzmann ThrombastheniaHematologyAug 2027
NCT07347249SutacimigPhase 2Congenital Factor VII DeficiencyHematologyNov 2027

Specialist investors

Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

F7 (1) TREML1 (1)

Companies with the same targets

Novo Nordisk CSL Behring

Companies built like this

Jiangsu BioJeTay Biotechnology Shanghai RAAS Blood Products Agios Pharmaceuticals Imara Prothya Biosolutions

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.